Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Part 1 Open-Label Extension:
Patients previously enrolled in etrolizumab Phase III study GA29144 (NCT02394028) who meet the eligibility criteria for open-label etrolizumab as described in the protocol
Part 2 Safety Monitoring:
You may not be if
Patients who transfer from Part 1
Completion of the 12-week safety follow-up period prior to entering
Part 1 Open-Label Extension:
Any new, significant, uncontrolled condition
Part 2 Safety Monitoring:
Clareo Health | Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
